Noteworthy Price Action: Can Curis, Inc.’s Tomorrow be Different? The Stock Declines Again

Noteworthy Price Action: Can Curis, Inc.'s Tomorrow be Different? The Stock Declines Again

The stock of Curis, Inc. (NASDAQ:CRIS) is a huge mover today! About 1.59M shares traded hands or 189.56% up from the average. Curis, Inc. (NASDAQ:CRIS) has risen 43.93% since April 27, 2016 and is uptrending. It has outperformed by 38.70% the S&P500.
The move comes after 9 months negative chart setup for the $392.31M company. It was reported on Nov, 30 by Barchart.com. We have $2.69 PT which if reached, will make NASDAQ:CRIS worth $27.46M less.

Analysts await Curis, Inc. (NASDAQ:CRIS) to report earnings on March, 6. They expect $-0.08 earnings per share, up 20.00% or $0.02 from last year’s $-0.1 per share. After $-0.12 actual earnings per share reported by Curis, Inc. for the previous quarter, Wall Street now forecasts -33.33% EPS growth.

Curis, Inc. (NASDAQ:CRIS) Ratings Coverage

Out of 4 analysts covering Curis (NASDAQ:CRIS), 3 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 75% are positive. Curis has been the topic of 6 analyst reports since August 10, 2015 according to StockzIntelligence Inc. As per Tuesday, August 11, the company rating was initiated by FBR Capital. The stock has “Buy” rating given by TH Capital on Monday, November 9. Zacks downgraded Curis, Inc. (NASDAQ:CRIS) on Monday, September 21 to “Sell” rating. The firm has “Hold” rating given on Tuesday, September 1 by Zacks. The firm has “Buy” rating by Roth Capital given on Monday, November 9.

According to Zacks Investment Research, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease.”

Insitutional Activity: The institutional sentiment decreased to 1.21 in Q2 2016. Its down 0.57, from 1.78 in 2016Q1. The ratio turned negative, as 8 funds sold all Curis, Inc. shares owned while 15 reduced positions. 11 funds bought stakes while 30 increased positions. They now own 67.45 million shares or 4.41% less from 70.56 million shares in 2016Q1.
First Ny Securities Llc Ny owns 12,000 shares or 0% of their US portfolio. Bnp Paribas Arbitrage holds 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS) for 4,868 shares. The New York-based Millennium Mngmt Limited Liability Company has invested 0% in Curis, Inc. (NASDAQ:CRIS). Blackrock Fund holds 4.59 million shares or 0% of its portfolio. State Street Corporation has 0% invested in the company for 1.58M shares. Renaissance Techs Limited Liability Corp has 0% invested in the company for 39,400 shares. Meridian Inv Counsel accumulated 10,000 shares or 0.01% of the stock. Jacobs Levy Equity Management Inc reported 229,672 shares or 0.01% of all its holdings. Royal National Bank & Trust Of Canada owns 811,129 shares or 0% of their US portfolio. Barclays Pcl last reported 64,059 shares in the company. Nationwide Fund Advsrs holds 75,161 shares or 0% of its portfolio. Susquehanna International Gru Llp owns 25,154 shares or 0% of their US portfolio. Bridgeway Capital Inc accumulated 0.01% or 277,725 shares. Ny State Common Retirement Fund holds 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS) for 101,500 shares. D E Shaw Communication last reported 601,527 shares in the company.

Another recent and important Curis, Inc. (NASDAQ:CRIS) news was published by Seekingalpha.com which published an article titled: “Curis: One Swallow Doesn’t Make A Summer” on November 22, 2016.

CRIS Company Profile

Curis, Inc., incorporated on February 14, 2000, is a biotechnology company. The Firm is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment